News & Updates
Filter by Specialty:
Risankizumab eases symptoms in nonpustular palmoplantar psoriasis
In patients with nonpustular palmoplantar psoriasis (nPPP), treatment with risankizumab relieves disease symptoms, such as skin pain in palms or soles of feet, by week 16, as shown by the results of a post hoc analysis of the phase IIIb IMMprint study. These improvements persist up to week 52.
Risankizumab eases symptoms in nonpustular palmoplantar psoriasis
12 Oct 2024
Long-term secukinumab safe, effective in kids with plaque psoriasis
Long-term treatment with secukinumab, either at low or high dose, results in sustained efficacy and better health-related quality of life up to 4 years in children and adolescents with moderate-to-severe chronic plaque psoriasis, as shown in a phase III study presented at EADV 2024.
Long-term secukinumab safe, effective in kids with plaque psoriasis
11 Oct 2024
COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.
